Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Zaltenibart is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 ...

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of advanced prostate cancer, including homologous recombination repair (HRR) gene alterations. Identifying the ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...